WO1995026334A1 - Substituted azetidinone compounds useful as hypocholesterolemic agents - Google Patents
Substituted azetidinone compounds useful as hypocholesterolemic agents Download PDFInfo
- Publication number
- WO1995026334A1 WO1995026334A1 PCT/US1995/003196 US9503196W WO9526334A1 WO 1995026334 A1 WO1995026334 A1 WO 1995026334A1 US 9503196 W US9503196 W US 9503196W WO 9526334 A1 WO9526334 A1 WO 9526334A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aryl
- lower alkyl
- formula
- compound
- azetidinone
- Prior art date
Links
- 0 C*CNC(CC(O*)=O)*C Chemical compound C*CNC(CC(O*)=O)*C 0.000 description 4
- MMNZCESXFOCVMF-YPAWHYETSA-N O[C@H](COc(cc1)ccc1F)[C@H]([C@@H](c(cc1)ccc1O)N1c(cc2)ccc2F)C1=O Chemical compound O[C@H](COc(cc1)ccc1F)[C@H]([C@@H](c(cc1)ccc1O)N1c(cc2)ccc2F)C1=O MMNZCESXFOCVMF-YPAWHYETSA-N 0.000 description 2
- WPHGVVJFRZHBKW-DHIUTWEWSA-N C=C[C@H]([C@@H](c(cc1)ccc1OCc1ccccc1)N1c(cc2)ccc2F)C1=O Chemical compound C=C[C@H]([C@@H](c(cc1)ccc1OCc1ccccc1)N1c(cc2)ccc2F)C1=O WPHGVVJFRZHBKW-DHIUTWEWSA-N 0.000 description 1
- UAEPNZWRGJTJPN-UHFFFAOYSA-N CC1CCCCC1 Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 1
- YXEYFHKAZYKWJN-UHFFFAOYSA-N COc1ccc(C(C(C(CS(c(cc2)ccc2F)O)O)C2=O)N2c2ccccc2)cc1 Chemical compound COc1ccc(C(C(C(CS(c(cc2)ccc2F)O)O)C2=O)N2c2ccccc2)cc1 YXEYFHKAZYKWJN-UHFFFAOYSA-N 0.000 description 1
- MEGVKAJMWJCVFR-DNVJHFABSA-N COc1ccc([C@H]([C@@H]([C@@H](CS(c(cc2)ccc2F)(O)O)O)C2=O)N2c2ccccc2)cc1 Chemical compound COc1ccc([C@H]([C@@H]([C@@H](CS(c(cc2)ccc2F)(O)O)O)C2=O)N2c2ccccc2)cc1 MEGVKAJMWJCVFR-DNVJHFABSA-N 0.000 description 1
- HWGWDJMHZKGCPW-NRFANRHFSA-N O=C(C[C@H]1c(cc2)ccc2OCc2ccccc2)N1c(cc1)ccc1F Chemical compound O=C(C[C@H]1c(cc2)ccc2OCc2ccccc2)N1c(cc1)ccc1F HWGWDJMHZKGCPW-NRFANRHFSA-N 0.000 description 1
- MQTDPBMTQJBZEO-WELAQSEPSA-N O=C([C@H]([C@@H]1OC1)C1c(cc2)ccc2OCc2ccccc2)N1c(cc1)ccc1F Chemical compound O=C([C@H]([C@@H]1OC1)C1c(cc2)ccc2OCc2ccccc2)N1c(cc1)ccc1F MQTDPBMTQJBZEO-WELAQSEPSA-N 0.000 description 1
- ATJFHEFBESTYKU-UHFFFAOYSA-N O=CCOc(cc1)ccc1F Chemical compound O=CCOc(cc1)ccc1F ATJFHEFBESTYKU-UHFFFAOYSA-N 0.000 description 1
- IWRLOPFBEDSNEF-DVZSQSHLSA-N OC([C@H]([C@H]1OC1)[C@H]1c(cc2)ccc2OCc2ccccc2)N1c(cc1)ccc1F Chemical compound OC([C@H]([C@H]1OC1)[C@H]1c(cc2)ccc2OCc2ccccc2)N1c(cc1)ccc1F IWRLOPFBEDSNEF-DVZSQSHLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/30—Preparation of optical isomers
- C07C227/32—Preparation of optical isomers by stereospecific synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002186364A CA2186364C (en) | 1994-03-25 | 1995-03-22 | Substituted azetidinone compounds useful as hypocholesterolemic agents |
DK95914719T DK0751934T3 (en) | 1994-03-25 | 1995-03-22 | Substituted azetidinone compounds which can be used as hypocholesterolemic agents |
NZ283528A NZ283528A (en) | 1994-03-25 | 1995-03-22 | Azetidinone derivatives; medicaments; precursors |
KR1019960705349A KR100338171B1 (en) | 1994-03-25 | 1995-03-22 | Substituted Azetidinone Compounds Useful as Low Cholesterol Type Thickeners |
HU9602616A HU221309B1 (en) | 1994-03-25 | 1995-03-22 | Substituted azetidinone compounds useful as hypocholesterolemic agents, pharmaceutical compositions containing the same, intermediates and process for producing them |
SK1197-96A SK119796A3 (en) | 1994-03-25 | 1995-03-22 | Substituted azetidinone compounds useful as hypocholesterolemic agents |
JP52518495A JP3524927B2 (en) | 1994-03-25 | 1995-03-22 | Substituted azetidinone compounds useful as hypocholesterolemic agents |
AU21596/95A AU686361B2 (en) | 1994-03-25 | 1995-03-22 | Substituted azetidinone compounds useful as hypocholesterolemic agents |
EP95914719A EP0751934B1 (en) | 1994-03-25 | 1995-03-22 | Substituted azetidinone compounds useful as hypocholesterolemic agents |
DE69511687T DE69511687T2 (en) | 1994-03-25 | 1995-03-22 | SUBSTITUTED AZETIDINONE COMPOUNDS AS A HYPOCHOLESTEROLEMIC AGENT |
MXPA/A/1996/004030A MXPA96004030A (en) | 1994-03-25 | 1996-09-11 | Azetidinone compounds substituted useful as agents hipocolesterolemi |
NO964008A NO964008L (en) | 1994-03-25 | 1996-09-24 | Substituted azetidinone compounds useful as hypocholesterolemic agents |
FI963817A FI963817A0 (en) | 1994-03-25 | 1996-09-25 | Substituted azetidinone compounds useful as hypocholesterolemic agents |
GR990402188T GR3031105T3 (en) | 1994-03-25 | 1999-08-27 | Substituted azetidinone compounds useful as hypocholesterolemic agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21849894A | 1994-03-25 | 1994-03-25 | |
US08/218,498 | 1994-03-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995026334A1 true WO1995026334A1 (en) | 1995-10-05 |
Family
ID=22815366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/003196 WO1995026334A1 (en) | 1994-03-25 | 1995-03-22 | Substituted azetidinone compounds useful as hypocholesterolemic agents |
Country Status (20)
Country | Link |
---|---|
US (2) | US5627176A (en) |
EP (1) | EP0751934B1 (en) |
JP (1) | JP3524927B2 (en) |
KR (1) | KR100338171B1 (en) |
CN (1) | CN1144522A (en) |
AT (1) | ATE183738T1 (en) |
AU (1) | AU686361B2 (en) |
CA (1) | CA2186364C (en) |
CZ (1) | CZ281596A3 (en) |
DE (1) | DE69511687T2 (en) |
DK (1) | DK0751934T3 (en) |
ES (1) | ES2135050T3 (en) |
FI (1) | FI963817A0 (en) |
GR (1) | GR3031105T3 (en) |
HU (1) | HU221309B1 (en) |
NO (1) | NO964008L (en) |
NZ (1) | NZ283528A (en) |
PL (1) | PL316431A1 (en) |
SK (1) | SK119796A3 (en) |
WO (1) | WO1995026334A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996016037A1 (en) * | 1994-11-18 | 1996-05-30 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5624920A (en) * | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
WO1997016424A1 (en) * | 1995-11-02 | 1997-05-09 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone |
US5756470A (en) * | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
US6627757B2 (en) | 2001-03-28 | 2003-09-30 | Schering Corporation | Enantioselective synthesis of azetidinone intermediate compounds |
EP1911462A2 (en) | 2001-01-26 | 2008-04-16 | Schering Corporation | Compositions comprising a sterol absorption inhibitor |
EP1918000A2 (en) | 2003-11-05 | 2008-05-07 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
WO2008108486A1 (en) | 2007-03-06 | 2008-09-12 | Teijin Pharma Limited | 1-biarylazetidinone derivatives |
US7470678B2 (en) | 2002-07-05 | 2008-12-30 | Astrazeneca Ab | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism |
WO2010100255A1 (en) | 2009-03-06 | 2010-09-10 | Lipideon Biotechnology Ag | Pharmaceutical hypocholesterolemic compositions |
US7795229B2 (en) | 2003-06-27 | 2010-09-14 | Kotobuki Pharmaceutical Co., Ltd. | Serum cholesterol lowering agent or preventative or therapeutic agent for atherosclerosis |
US7842684B2 (en) | 2006-04-27 | 2010-11-30 | Astrazeneca Ab | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity |
CZ302193B6 (en) * | 2000-12-20 | 2010-12-08 | Schering Corporation | Sugar-substituted 2-azetidinone derivatives |
US7871998B2 (en) | 2003-12-23 | 2011-01-18 | Astrazeneca Ab | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity |
WO2011017907A1 (en) | 2009-08-11 | 2011-02-17 | 浙江海正药业股份有限公司 | Azetidinone compounds and medical use thereof |
US7893048B2 (en) | 2005-06-22 | 2011-02-22 | Astrazeneca Ab | 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
AU4343500A (en) | 1999-04-16 | 2000-11-02 | Schering Corporation | Use of azetidinone compounds |
US6584357B1 (en) * | 2000-10-17 | 2003-06-24 | Sony Corporation | Method and system for forming an acoustic signal from neural timing difference data |
US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
PT1413331E (en) * | 2001-01-26 | 2007-12-18 | Schering Corp | Combinations of the peroxisome proliferator-activated receptor (ppar) activator fenofibrate with sterol absorption inhibitor ezetimibe for vascular indications |
JP2004517920A (en) * | 2001-01-26 | 2004-06-17 | シェーリング コーポレイション | Combination of sterol absorption inhibitors and blood conditioning agents to treat vascular conditions |
IL156422A0 (en) * | 2001-01-26 | 2004-01-04 | Schering Corp | The use of substituted azetidinone compounds for the treatment of sitosterolemia |
AU2005246926B2 (en) * | 2001-01-26 | 2008-02-28 | Merck Sharp & Dohme Corp. | The use of substituted azetidinone compounds for the treatment of sitosterolemia |
US7071181B2 (en) * | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
ATE345793T1 (en) * | 2001-09-21 | 2006-12-15 | Schering Corp | TREATMENT OF XANTHOMA USING AZETIDINONE DERIVATIVES AS STEROL ABSORPTION INHIBITORS |
SI1429756T1 (en) * | 2001-09-21 | 2007-02-28 | Schering Corp | Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors |
US7056906B2 (en) * | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
US20030204096A1 (en) * | 2002-03-25 | 2003-10-30 | Schering Corporation | Enantioselective synthesis of azetidinone intermediate compounds |
US20040132058A1 (en) | 2002-07-19 | 2004-07-08 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
US7135556B2 (en) * | 2002-07-19 | 2006-11-14 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
AR040588A1 (en) * | 2002-07-26 | 2005-04-13 | Schering Corp | PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE |
US7208486B2 (en) * | 2003-03-07 | 2007-04-24 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
US7235543B2 (en) * | 2003-03-07 | 2007-06-26 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
JP2007510659A (en) * | 2003-11-05 | 2007-04-26 | シェーリング コーポレイション | Combinations of lipid modulators and substituted azetidinones and treatment of vascular conditions |
WO2005062824A2 (en) * | 2003-12-23 | 2005-07-14 | Merck & Co., Inc. | Anti-hypercholesterolemic compounds |
EP1723414A4 (en) * | 2004-01-16 | 2008-03-26 | Merck & Co Inc | Npc1l1 (npc3) and methods of identifying ligands thereof |
JP2008514718A (en) * | 2004-09-29 | 2008-05-08 | シェーリング コーポレイション | Combinations of substituted azetidonones and CB1 antagonists |
JP5254620B2 (en) | 2004-12-03 | 2013-08-07 | メルク・シャープ・アンド・ドーム・コーポレーション | Substituted piperazines as CB1 antagonists |
KR20080021082A (en) * | 2005-06-20 | 2008-03-06 | 쉐링 코포레이션 | Piperidine derivatives useful as histamine h3 antagonists |
CA2637565A1 (en) | 2006-01-18 | 2007-07-26 | Schering Corporation | Cannibinoid receptor modulators |
US7910698B2 (en) | 2006-02-24 | 2011-03-22 | Schering Corporation | NPC1L1 orthologues |
EP1849459A1 (en) * | 2006-03-06 | 2007-10-31 | Teva Pharmaceutical Industries Ltd. | Ezetimibe compositions |
US20100197564A1 (en) * | 2007-04-19 | 2010-08-05 | Schering Corporation | Diaryl morpholines as cb1 modulators |
US20090047716A1 (en) * | 2007-06-07 | 2009-02-19 | Nurit Perlman | Reduction processes for the preparation of ezetimibe |
KR20100051625A (en) * | 2007-06-28 | 2010-05-17 | 인터벳 인터내셔널 비.브이. | Substituted piperazines as cb1 antagonists |
WO2009005671A2 (en) * | 2007-06-28 | 2009-01-08 | Schering Corporation | Substituted piperazines as cb1 antagonists |
WO2009032264A1 (en) * | 2007-08-30 | 2009-03-12 | Teva Pharmaceutical Industries Ltd. | Processes for preparing intermediates of ezetimibe by microbial reduction |
CN101200443B (en) * | 2007-10-17 | 2011-06-29 | 中国药科大学 | Nitrogen heterocyclic methyl ethyl ketone derivatives, preparation method and medicine combination containing the same |
MX365046B (en) | 2012-05-01 | 2019-05-17 | Althera Life Sciencies Llc | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases. |
JP5969958B2 (en) * | 2013-06-27 | 2016-08-17 | 国立大学法人お茶の水女子大学 | Process for producing optically active fluorinated amino acids |
CN105294426B (en) * | 2014-06-09 | 2019-05-14 | 浙江海正药业股份有限公司 | Azetidinone compounds Preparation Method And Their Intermediate |
CN104860980B (en) * | 2015-04-23 | 2018-06-19 | 上海弈柯莱生物医药科技有限公司 | It is a kind of to be used to synthesize intermediate of Ezetimibe and its preparation method and application |
US20200129440A1 (en) | 2017-01-23 | 2020-04-30 | Dong Wha Pharm. Co., Ltd. | Complex formulation comprising hmg-coa reductase inhibitor and clopidogrel |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02268144A (en) * | 1989-04-11 | 1990-11-01 | Ube Ind Ltd | Production of beta-amino ester |
EP0524595A1 (en) * | 1991-07-23 | 1993-01-27 | Schering Corporation | Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
US4803266A (en) * | 1986-10-17 | 1989-02-07 | Taisho Pharmaceutical Co., Ltd. | 3-Oxoalkylidene-2-azetidinone derivatives |
NZ228600A (en) * | 1988-04-11 | 1992-02-25 | Merck & Co Inc | 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives |
US4983597A (en) * | 1989-08-31 | 1991-01-08 | Merck & Co., Inc. | Beta-lactams as anticholesterolemic agents |
US5120729A (en) * | 1990-06-20 | 1992-06-09 | Merck & Co., Inc. | Beta-lactams as antihypercholesterolemics |
-
1995
- 1995-03-13 US US08/403,081 patent/US5627176A/en not_active Expired - Lifetime
- 1995-03-22 CZ CZ962815A patent/CZ281596A3/en unknown
- 1995-03-22 KR KR1019960705349A patent/KR100338171B1/en not_active IP Right Cessation
- 1995-03-22 CN CN95192277A patent/CN1144522A/en active Pending
- 1995-03-22 AU AU21596/95A patent/AU686361B2/en not_active Ceased
- 1995-03-22 AT AT95914719T patent/ATE183738T1/en not_active IP Right Cessation
- 1995-03-22 WO PCT/US1995/003196 patent/WO1995026334A1/en active IP Right Grant
- 1995-03-22 NZ NZ283528A patent/NZ283528A/en not_active IP Right Cessation
- 1995-03-22 EP EP95914719A patent/EP0751934B1/en not_active Expired - Lifetime
- 1995-03-22 HU HU9602616A patent/HU221309B1/en not_active IP Right Cessation
- 1995-03-22 SK SK1197-96A patent/SK119796A3/en unknown
- 1995-03-22 DK DK95914719T patent/DK0751934T3/en active
- 1995-03-22 DE DE69511687T patent/DE69511687T2/en not_active Expired - Lifetime
- 1995-03-22 ES ES95914719T patent/ES2135050T3/en not_active Expired - Lifetime
- 1995-03-22 JP JP52518495A patent/JP3524927B2/en not_active Expired - Fee Related
- 1995-03-22 PL PL95316431A patent/PL316431A1/en unknown
- 1995-03-22 CA CA002186364A patent/CA2186364C/en not_active Expired - Fee Related
- 1995-05-18 US US08/444,167 patent/US5688990A/en not_active Expired - Lifetime
-
1996
- 1996-09-24 NO NO964008A patent/NO964008L/en unknown
- 1996-09-25 FI FI963817A patent/FI963817A0/en unknown
-
1999
- 1999-08-27 GR GR990402188T patent/GR3031105T3/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02268144A (en) * | 1989-04-11 | 1990-11-01 | Ube Ind Ltd | Production of beta-amino ester |
EP0524595A1 (en) * | 1991-07-23 | 1993-01-27 | Schering Corporation | Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof |
WO1993002048A1 (en) * | 1991-07-23 | 1993-02-04 | Schering Corporation | Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof |
Non-Patent Citations (3)
Title |
---|
CHEMICAL ABSTRACTS, vol. 109, no. 5, 1 August 1988, Columbus, Ohio, US; abstract no. 38139, I. PANFIL: "An entry to the optically pure beta-lactam skeleton based on 1,3-dipolar cycloaddition of nitrones to 4,6-di-O-acetyl-2,3-dideoxy-D-threo-hex-2-enono-1,5-lactone." * |
CHEMICAL ABSTRACTS, vol. 114, no. 19, 13 May 1991, Columbus, Ohio, US; abstract no. 185021, M. MUKOYAMA: "Preparation of beta-amino esters as intermediates for beta-lactams." * |
J. CARBOHYDR. CHEM., vol. 6, no. 3, ENG., pages 463 - 470 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996016037A1 (en) * | 1994-11-18 | 1996-05-30 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5624920A (en) * | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5633246A (en) * | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5744467A (en) * | 1994-11-18 | 1998-04-28 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
WO1997016424A1 (en) * | 1995-11-02 | 1997-05-09 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone |
US5856473A (en) * | 1995-11-02 | 1999-01-05 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(R)-(3(S)-hydroxy-3-( phenyl or 4-fluorophenyl!)-propyl)-4(S)-(4-hydroxyphenyl)-2-azetidinone |
US5756470A (en) * | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
CZ302193B6 (en) * | 2000-12-20 | 2010-12-08 | Schering Corporation | Sugar-substituted 2-azetidinone derivatives |
EP1911462A2 (en) | 2001-01-26 | 2008-04-16 | Schering Corporation | Compositions comprising a sterol absorption inhibitor |
US6627757B2 (en) | 2001-03-28 | 2003-09-30 | Schering Corporation | Enantioselective synthesis of azetidinone intermediate compounds |
US7470678B2 (en) | 2002-07-05 | 2008-12-30 | Astrazeneca Ab | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism |
US7795229B2 (en) | 2003-06-27 | 2010-09-14 | Kotobuki Pharmaceutical Co., Ltd. | Serum cholesterol lowering agent or preventative or therapeutic agent for atherosclerosis |
EP1918000A2 (en) | 2003-11-05 | 2008-05-07 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
US7871998B2 (en) | 2003-12-23 | 2011-01-18 | Astrazeneca Ab | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity |
US7893048B2 (en) | 2005-06-22 | 2011-02-22 | Astrazeneca Ab | 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
US7842684B2 (en) | 2006-04-27 | 2010-11-30 | Astrazeneca Ab | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity |
WO2008108486A1 (en) | 2007-03-06 | 2008-09-12 | Teijin Pharma Limited | 1-biarylazetidinone derivatives |
WO2010100255A1 (en) | 2009-03-06 | 2010-09-10 | Lipideon Biotechnology Ag | Pharmaceutical hypocholesterolemic compositions |
US9212175B2 (en) | 2009-03-06 | 2015-12-15 | Lipideon Biotechnology Ag | Pharmaceutical hypocholesterolemic compositions |
WO2011017907A1 (en) | 2009-08-11 | 2011-02-17 | 浙江海正药业股份有限公司 | Azetidinone compounds and medical use thereof |
US8623855B2 (en) | 2009-08-11 | 2014-01-07 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Azetidinone compounds and medical use thereof |
Also Published As
Publication number | Publication date |
---|---|
PL316431A1 (en) | 1997-01-06 |
DE69511687D1 (en) | 1999-09-30 |
AU686361B2 (en) | 1998-02-05 |
GR3031105T3 (en) | 1999-12-31 |
MX9604030A (en) | 1997-09-30 |
CN1144522A (en) | 1997-03-05 |
DK0751934T3 (en) | 1999-12-13 |
AU2159695A (en) | 1995-10-17 |
ES2135050T3 (en) | 1999-10-16 |
CA2186364A1 (en) | 1995-10-05 |
CA2186364C (en) | 2008-12-30 |
ATE183738T1 (en) | 1999-09-15 |
JP3524927B2 (en) | 2004-05-10 |
US5688990A (en) | 1997-11-18 |
HU9602616D0 (en) | 1996-11-28 |
FI963817A (en) | 1996-09-25 |
NZ283528A (en) | 1997-12-19 |
KR100338171B1 (en) | 2002-11-23 |
DE69511687T2 (en) | 2000-03-16 |
CZ281596A3 (en) | 1997-05-14 |
EP0751934A1 (en) | 1997-01-08 |
HUT74887A (en) | 1997-02-28 |
EP0751934B1 (en) | 1999-08-25 |
SK119796A3 (en) | 1997-05-07 |
JPH09510970A (en) | 1997-11-04 |
KR970702246A (en) | 1997-05-13 |
NO964008D0 (en) | 1996-09-24 |
FI963817A0 (en) | 1996-09-25 |
HU221309B1 (en) | 2002-09-28 |
NO964008L (en) | 1996-11-22 |
US5627176A (en) | 1997-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0751934B1 (en) | Substituted azetidinone compounds useful as hypocholesterolemic agents | |
EP0720599B1 (en) | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents | |
US5624920A (en) | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents | |
EP0792264B1 (en) | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents | |
EP0681569B1 (en) | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents | |
US5688785A (en) | Substituted azetidinone compounds useful as hypocholesterolemic agents | |
EP0766667A1 (en) | Substituted azetidinone compounds useful as hypocholesterolemic agents | |
MXPA96004030A (en) | Azetidinone compounds substituted useful as agents hipocolesterolemi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95192277.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KG KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 283528 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1996/004030 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995914719 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 119796 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2186364 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 963817 Country of ref document: FI Ref document number: PV1996-2815 Country of ref document: CZ Ref document number: 1019960705349 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1995914719 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1996-2815 Country of ref document: CZ |
|
WWR | Wipo information: refused in national office |
Ref document number: PV1996-2815 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995914719 Country of ref document: EP |